July

Blog Posts in July, 2015

Blog Home
  • Zofran Litigation May See MDL Consolidation

    Posted By Golomb & Honik, P.C. || 29-Jul-2015

    GlaxoSmithKline, the manufacturer of Zofran, recently submitted a motion asking for consolidation of all Zofran lawsuits claiming birth defects into a multi-district litigation. The motion requested Pennsylvania as the consolidation venue, likely due to the fact the Philadelphia Navy Yard is where GSK’s headquarters are located. MDL consolidation contributes to a more efficient process for ...
    Continue Reading
  • Pfizer Executives Warned about the Link Between Zoloft and Birth Defects

    Posted By Golomb & Honik, P.C. || 29-Jul-2015

    Just last year one of Pfizer’s own scientists warned top executives about a possible link between birth defects and the anti-depressant drug Zoloft. At that time, changes were recommended regarding changes to the safety warnings on the drug. The document clearly shows Pfizer was warned of Zoloft’s potential risks and would seem to complicate the more than 1,000 lawsuits brought by ...
    Continue Reading
  • Eye Hemorrhaging and Stomach Bleeds Tied to Xarelto

    Posted By Golomb & Honik, P.C. || 28-Jul-2015

    Two recent studies have linked Xarelto, a blood-thinning drug manufactured by Johnson & Johnson, to an increased risk of stomach bleeds and eye hemorrhaging. In the first study, two doctors found a significant number of patients in their 70’s and 80’s who switched from Warfarin to Xarelto suffered a bleed between the lens of the eye and the retina. These cases were reported in the ...
    Continue Reading
  • Regions Bank Fined $7.5 Million for Overdraft Fees

    Posted By Golomb & Honik, P.C. || 27-Jul-2015

    The Consumer Financial Protection Bureau will be collecting more than $7.5 million in fines alone from Regions Financial Corporation. These fines were imposed for overdraft fees charged to consumers who had not agreed to a service, which would transfer money to protect in the case of a shortfall. Regions Financial refunded $49 million to customers who erroneously received NSF fees. In short, the ...
    Continue Reading
  • New Study Shows Xarelto Doubles Risk of Gastrointestinal Bleeding

    Posted By Golomb & Honik, P.C. || 22-Jul-2015

    Xarelto is a newer blood thinner that has been on the market since 2011. Its primary function is to reduce the risk of blood clots in patients who have Deep Vein Thrombosis, pulmonary embolism, or have undergone a knee or hip replacement. Unlike older blood thinners, such as Heparin or Coumadin, patients taking Xarelto do not need to undergo regular blood testing and there are fewer known drug and ...
    Continue Reading
  • The Status of Invokana Lawsuits

    Posted By Golomb & Honik, P.C. || 20-Jul-2015

    A potentially fatal side effect of Invokana, as well as other SGLT2 inhibitors, is expected to lead to a flurry of lawsuits against the manufacturers of these drugs. Invokana is used in the treatment of Type II diabetes. Yet, this drug can trigger dangerous levels of blood acids, which can lead to coma and even death. After reviewing 20 adverse event reports, the FDA issued a warning regarding ...
    Continue Reading
  • Shire Sued By Consumers For "Pay For Delay"

    Posted By Golomb & Honik, P.C. || 15-Jul-2015

    Adderall manufacturer, Shire Pharmaceuticals, cannot seem to stay out of trouble with the U.S. Dept. of Justice and consumers. First, in October 2014, the company settled claims of deceptive marketing and agreed to pay more than $56.5 million. Now, they have been sued because of a “Pay for Delay” scheme with a generic drug manufacturer resulting in higher prices to consumers in ...
    Continue Reading
  • Legal Battle Intensifies Over Link between Talcum Powder & Ovarian Cancer

    Posted By Golomb & Honik, P.C. || 15-Jul-2015

    More than 700 lawsuits have been filed nationally in courts against Johnson & Johnson, claiming talcum powder contributed to their ovarian cancer. Many women found out—much too late—that the consistent use of talc powder in the genital area was the precipitating factor in a later diagnosis of ovarian cancer. Since the early 1980’s, more than 20 studies on talcum powder have ...
    Continue Reading
  • Plaintiffs Uphold Class Certification of Overdraft MDL Against Wells Fargo

    Posted By Golomb & Honik, P.C. || 13-Jul-2015

    Consumers of Wells Fargo pushed back when the bank prompted the court to reconsider arguments of deceptive overdraft fees. The Florida-based multidistrict litigation alleges that the motion from Wells Fargo did little more than replay arguments previously heard by the court in a 260-page evidentiary submission and briefs opposing challenging certification of the claims. The plaintiffs said, ...
    Continue Reading
  • Johnson & Johnson Pays Millions to Settle Risperdal Lawsuit

    Posted By Golomb & Honik, P.C. || 8-Jul-2015

    The state of Arkansas will receive $7.8 million from Johnson & Johnson to settle claims by the state that J & J illegally marketed the antipsychotic drug, Risperdal. The original $1.2 billion award against J & J was thrown out, and the settlement which is less than one percent of that fine was eventually agreed on. The Arkansas Supreme Court overturned the first verdict based on their ...
    Continue Reading
  • 10 results found. Viewing page 1 of 1.